ライフサイエンスコーパス: dementia

1 ntia, frontotemporal dementia, and Alzheimer dementia).

2 Neither supplement prevented dementia.

3 te to early cognitive decline and (vascular) dementia.

4 sion (BCCAO) was used as a model of vascular dementia.

5 der adults with mild cognitive impairment or dementia.

6 n effect on cognition or QoL for people with dementia.

7 c lateral sclerosis (ALS) and frontotemporal dementia.

8 ous system injury in a rat model of vascular dementia.

9 er's disease (AD) is the most common form of dementia.

10 sion from mild cognitive impairment (MCI) to dementia.

11 re the onset of mild cognitive impairment or dementia.

12 ates of cognitive decline and progression to dementia.

13 trophic lateral sclerosis and frontotemporal dementia.

14 tter eating performance among residents with dementia.

15 onic/recurring, do not increase the risk for dementia.

16 e whether depressive symptoms carry risk for dementia.

17 nd white matter hyperintensities, as well as dementia.

18 enting space, memory formation, epilepsy and dementia.

19 DT were associated with an increased risk of dementia.

20 hese lesions and cerebrovascular disease and dementia.

21 areas known to be most affected in semantic dementia.

22 f health professionals' care for people with dementia.

23 e activities for nursing home residents with dementia.

24 or audit and feedback, health personnel, and dementia.

25 cognitive function in aging and Alzheimer's dementia.

26 od, 30 of 114 participants (26.3%) developed dementia.

27 ) underlie episodic-memory impairments in AD dementia.

28 up psychosocial intervention for people with dementia.

29 ar dementia, and 250 men developed all-cause dementia.

30 between proton pump inhibitor (PPI) use and dementia.

31 ker for this state and the development of PD dementia.

32 ected of playing a role in development of AD dementia.

33 tential new disease-modifying treatments for dementia.

34 imer disease, the leading cause of late-life dementia.

35 cognitive performance, and family history of dementia.

36 ay delay progression from MCI to Alzheimer's dementia.

37 us and corpus callosum in rats with vascular dementia.

38 been associated with Parkinson's disease and dementia.

39 younger delirious patients without baseline dementia.

40 decisions on the ethical dilemmas raised by dementia.

41 c areas, including cancer, inflammation, and dementia.

42 rate the trajectory of cognitive decline and dementia.

43 fespan and is an established risk factor for dementia.

44 increase the quality of care for people with dementia.

45 ood-based biomarker for neurodegeneration in dementias.

46 volume loss compared with controls and other dementias.

47 generation and segregation between different dementias.

48 dent parkinsonism, 24 (30.4%) also developed dementia (10 before and 14 after parkinsonism onset).

49 risk of mild cognitive impairment (MCI) and dementia; (2) whether this association differs by the pr

50 r (9 more cases [95% CI, 1 to 19]), probable dementia (22 more cases [95% CI, 4 to 53]), gallbladder

51 55 were women (49.1%), and 27 progressed to dementia (24.1%), with an incidence rate of 121 per 1000

52 012, we identified 243 611 incident cases of dementia, 31 577 cases of Parkinson's disease, and 9247

53 -up of 6.9 years, 123 participants developed dementia (97 Alzheimer disease).

54 ssion from normal aging to Alzheimer disease dementia (AD) has also been observed.

55 SMS was associated with a 28% higher risk of dementia (adjusted hazard ratio [aHR], 1.28; 95% CI, 1.1

56 end points were AD dementia and any type of dementia after 1 and 3 years.

57 recognized as the second most common form of dementia after Alzheimer's disease, and there is increas

58 ant acceleration in the rate of diagnosis of dementia after the introduction of the UK National Demen

59 vely, in clinical subtypes of frontotemporal dementia against neurologically normal controls.

60 cohort, MI was not associated with all-cause dementia (aHR, 1.01; 95% confidence interval [CI], 0.98-

61 enia, bipolar disorder, Tourette's syndrome, dementia, alcohol-induced delusions and obsessive-compul

62 re not significantly associated with risk of dementia (all-cause dementia or Alzheimer disease).

63 veal new information about neurodegenerative dementias, although challenges may include increased art

64 sease-associated dementia and HIV-associated dementia among others.

65 A total of 73731 patients with dementia and 733653 controls (median age, 80.3 years; in

66 er KT recipients have a high risk of post-KT dementia and AD, and these sequelae associate with a pro

67 a kidney transplant (KT) may develop post-KT dementia and Alzheimer's disease (AD) associated with th

68 Clinical end points were AD dementia and any type of dementia after 1 and 3 years.

69 g the association of vitamin D with incident dementia and cognitive impairment have been inconsistent

70 onths' duration that enrolled adults without dementia and compared cognitive outcomes with an OTC sup

71 r between behavioural variant frontotemporal dementia and controls for pleasant or neutral smells.

72 ngly involved in spatial navigation, memory, dementia and epilepsy.

73 ralistic conversations between patients with dementia and familial caregivers.

74 imer's Disease [QoL-AD]) for the person with dementia and general health status (Short Form-12 health

75 anulin-boosting therapies for frontotemporal dementia and highlight an important role for neuron-deri

76 sorders such as Parkinson disease-associated dementia and HIV-associated dementia among others.

77 optimal treatment and care for patients with dementia and support caregivers using a computer-assiste

78 sleep related symptoms, rapidly progressive dementia and sympathetic symptoms.

79 ting up-to-standard data with a diagnosis of dementia and the number and proportion of these with a p

80 nd gait speed in elderly individuals without dementia and to study the influence of cognition and APO

81 Subjects who died with dementia and were without severe neurodegenerative patho

82 ive with svPPA and two with 'right' semantic dementia) and 12 healthy controls underwent positron emi

83 Alzheimer disease, 64 men developed vascular dementia, and 250 men developed all-cause dementia.

84 similar after excluding those with incident dementia, and again most profound in individuals with hi

85 dementia, vascular dementia, frontotemporal dementia, and Alzheimer dementia).

86 MM40 with behavioural variant frontotemporal dementia, and ARHGAP35 and SERPINA1 with progressive non

87 y of hemorrhagic stroke, hypothyroidism, and dementia, and less likely to be treated in a facility wi

88 val from onset of motor symptoms to onset of dementia, and overall survival in groups with varying le

89 nset of debilitating and progressive chorea, dementia, and psychological disturbance.

90 inal detachment, reoperation within 30 days, dementia, anxiety disorder, hearing difficulty, or histo

91 IFICANCE STATEMENT Cognitive dysfunction and dementia are common features of Parkinson's disease (PD)

92 ATEMENT Alzheimer's disease (AD) and similar dementias are common incurable neurodegenerative disorde

93 ng and classification of sexual behaviour in dementia as appropriate or inappropriate often applied i

94 had 2-fold greater atrophy and progressed to dementia at almost 5 times the rate of a cluster of 184

95 contributes to an increased risk to develop dementia at old age.

96 , the role of anticoagulation for preventing dementia attributed to AF is less established.

97 ressive symptoms compared with those without dementia became apparent 11 years (difference, 0.61; 95%

98 Of these, 128 249 (1.4%) had a diagnosis of dementia before the end of the study period.

99 ic was associated with a higher incidence of dementia, but not with Parkinson's disease or multiple s

100 er (MDD) in the elderly is a risk factor for dementia, but the precise biological basis remains unkno

101 ents with behavioural variant frontotemporal dementia (bvFTD) poses a daunting challenge for clinicia

102 ngualism may act as CR delaying the onset of dementia by approximately 4.5 y.

103 mortality, and determined risk of MCI and/or dementia by genotype and baseline age.

104 trophic lateral sclerosis and frontotemporal dementia (C9ALS/FTD).

105 ion in APOE4 carriers before the onset of AD dementia can be a promising approach to decrease the inc

106 Dementia care management (DCM) can increase the quality

107 Dementia care management is a model of collaborative car

108 tem, an adaptive, personalized, and scalable dementia care program.

109 ed rights based approach in the provision of dementia care.

110 ld indicate that a significant proportion of dementia cases in women is likely to be preventable by e

111 troke, and vascular cognitive impairment and dementia caused by mutations in NOTCH3 No therapies are

112 and the NHATS measured probable or possible dementia, classified per NHATS protocol.

113 ssibly responsible for atypical Parkinsonism/dementia clusters, via the consumption of edible Annonac

114 to 35-year adjusted hazard ratios (aHRs) for dementia, controlled for matching factors and adjusted f

115 Dementia diagnoses obtained from electronic health recor

116 hat used clinical registers for ascertaining dementia diagnoses, those which clinically examined all

117 ce, 0.61; 95% CI, 0.09-1.13; P = .02) before dementia diagnosis and became more than 9 times larger a

118 f depressive symptoms over 28 years prior to dementia diagnosis to determine whether depressive sympt

119 .2% died with an MCI diagnosis, 46.8% with a dementia diagnosis, and 13.9% with a diagnosis of intact

120 oss cognitive domains and increased risk for dementia diagnosis.

121 ackward time scale, shows that in those with dementia, differences in depressive symptoms compared wi

122 Most people with dementia do not receive timely diagnosis, preventing the

123 from 58 patients with incipient and manifest dementia due to AD were analyzed.

124 n+/- mice, an animal model of frontotemporal dementia due to GRN mutations.

125 and lower mortality and may reduce risk for dementia due to life-course factors.

126 te cancer with the subsequent development of dementia (eg, senile dementia, vascular dementia, fronto

127 targeting vascular risk may help to prevent dementia, even of the Alzheimer type.

128 Pathologically distinct dementias exhibit characteristic patterns of regional vo

129 Nursing home residents with dementia experience increased risk for compromised eatin

130 decline in LMCI and delays conversion to AD dementia for at least 1 year; however, this effect of IV

131 Aging after Elective Surgery study enrolled dementia-free adults >/=70 years old undergoing major sc

132 uction in antipsychotic drug prescription in dementia from 22.1% (4347 of 19 635) in 2005 to 11.4% (2

133 temporal uptake completely distinguished AD dementia from probable DLB.

134 e impairment (MCI), and 180 patients with AD dementia from the Alzheimer's Disease Neuroimaging Initi

135 t of dementia (eg, senile dementia, vascular dementia, frontotemporal dementia, and Alzheimer dementi

136 oimaging studies of apathy in frontotemporal dementia (FTD) attempting to refine a neurocircuitry mod

137 Frontotemporal dementia (FTD) encompasses a group of neurodegenerative

138 nction mutations in GRN cause frontotemporal dementia (FTD) with transactive response DNA-binding pro

139 nd Huntington's disease (HD), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), mul

140 generative diseases including frontotemporal dementia (FTD), which can be caused by mutations in the

141 Frontotemporal dementia (FTD)-causing mutations in the CHMP2B gene lead

142 c lateral sclerosis (ALS) and frontotemporal dementia (FTD).

143 cal, and genetic overlap with frontotemporal dementia (FTD).

144 and in vitro models of AD and frontotemporal dementia (FTD).

145 sporadic ALS (sALS), ALS with frontotemporal dementia (FTD-ALS), and Alzheimer's disease (AD), and fo

146 ral Sclerosis (ALS) and Frontotemporal Lobar Dementia (FTLD).

147 cidence will contribute to reduced burden of dementia given the aging of the population is not known.

148 Risk of MCI and dementia; global and domain-specific cognitive decline.

149 n to be useful targets for therapy of senile dementias.-Goetzl, E.

150 The AD dementia group had significantly higher AV-1451 uptake t

151 t difference in inflammatory markers between dementia groups and controls.

152 Older recipients with dementia had a 1.52-fold (95% confidence interval, 1.39

153 ral practice associated with newly diagnosed dementia has not been subject to substantial change in t

154 bolic syndrome, insulin resistance (IR), and dementia has recently been questioned, wherefore the aim

155 such as Alzheimer's disease (AD) and related Dementias has been a challenge.

156 ht or education, was associated with risk of dementia (hazard ratio [HR] = 2.03 [95% confidence inter

157 id not have significantly increased risk for dementia (hazard ratio [HR], 1.21; 95% CI, 0.95-1.54) in

158 suggest that representations of sexuality in dementia held by nursing home staff ranged from the perc

159 ith prior TBI who do not have a diagnosis of dementia, however, has not been well described.

160 er gait speed in elderly individuals without dementia; however, this association is weaker in those w

161 .03-1.19], p = 0.0044) and mixed or vascular dementia (HR = 1.21 [1.04-1.41], p = 0.0163).

162 ere associated with an increased risk of all dementia (HR per SD increase = 1.11 [1.03-1.19], p = 0.0

163 n (SD) age at the beginning of follow-up for dementia in 1996 was 71.14 (2.72) years.

164 A diagnosis of dementia in a hospital inpatient or outpatient contact.

165 may be associated with a lower incidence of dementia in a nonlinear way; however, confounding from o

166 requently misunderstood, with residents with dementia in a nursing home often viewed as asexual or in

167 The unadjusted rates for dementia in ADT recipients versus nonrecipients were 38.

168 prevent or delay cognitive decline, MCI, or dementia in adults with normal cognition or MCI.

169 ewy bodies is the second most common form of dementia in elderly people but has been overshadowed in

170 ed declining age-specific incidence rates of dementia in high-income countries over time.

171 s associated with the early onset of AD-type dementia in homozygous individuals, whereas it has a pro

172 The quality of care delivered to people with dementia in hospital settings is of international concer

173 Paget's disease of bone, and frontotemporal dementia in humans unfolds substrate faster, suggesting

174 environment arrangements for residents with dementia in nursing homes.

175 ve function and prevent cognitive decline or dementia in older adults is largely insufficient.

176 -task gait is associated with progression to dementia in patients with MCI.

177 d cognitive decline and an increased risk of dementia in the general population.

178 ssociated with mild cognitive impairment and dementia in various cross-sectional studies, but whether

179 ssociation of antioxidant supplement use and dementia incidence among asymptomatic men.

180 Data regarding dementia incidence were obtained using general-practitio

181 sis included 183 elderly individuals without dementia, including a cognitively normal (CN) subsample

182 ADT is associated with an increased risk of dementia, including Alzheimer's disease, in patients wit

183 INTRODUCTION: Semantic dementia, including the semantic variant of primary prog

184 Evidence-based care for people with dementia is a priority for patients, carers and clinicia

185 Delaying the onset of dementia is a top priority of modern societies, and the

186 the presence of the pathologic processes of dementia is associated with accelerated cognitive declin

187 nd Kenneth Langa discuss whether the risk of dementia is increasing or decreasing over time.

188 Vascular dementia is now recognized as the second most common for

189 prodromal phases of the disease suggest that dementia is the result of a series of molecular and cell

190 ersely, evidence for efficacy in people with dementia is weak and limited to trials of immersive tech

191 ognitive deficits associated with ageing and dementia, it was hypothesised that DBN protein abundance

192 DCM in the treatment and care of people with dementia living at home and caregiver burden (when avail

193 ed that with the loss of memory, people with dementia may also experience loss of interest in sexuali

194 The sample included 15 residents with dementia (mean age=86), and 19 certified nursing assista

195 h MCI (mean, 42.8 ng/L) and patients with AD dementia (mean, 51.0 ng/L) compared with controls (mean,

196 fferent between patients with a diagnosis of dementia (median, 11.5 microg/L; interquartile range, 6.

197 erate risk of bias (including 3 that studied dementia medications, 16 antihypertensives, 4 diabetes m

198 In tauopathy-frontotemporal dementia mice, both drugs were neuroprotective, rescued

199 ized that behavioural variant frontotemporal dementia might also be associated with altered energy ex

200 ymptomatic carriers of common frontotemporal dementia mutations is affected by both genetic and envir

201 Incidence of dementia (n = 322) between 1985 and 2015.

202 ognitive performance, cognitive decline, and dementia (N dementia/total = 195/7,499).

203 o anticipate a dramatic absolute increase in dementia occurrence over the years to come.

204 ATEMENT Individuals with Parkinson's disease dementia often suffer a characteristic deficit in "cogni

205 ssociated with an increased risk of incident dementia or AD in Eastern Finnish men.

206 associated with risk of dementia (all-cause dementia or Alzheimer disease).

207 (6.2 times higher likelihood to develop MCI, dementia or die than healthy controls).

208 adults aged 55-85 years (about 2.2 million; dementia or Parkinson's disease cohort) who resided in O

209 ed graft loss and mortality after developing dementia or the AD subtype of dementia, separately, usin

210 at concurrent delirium, psychiatric disease, dementia, or a second lesion is required.

211 95% CI -1.22-0.82; p = 0.97) for people with dementia, or caregivers' general health status (MD = 0.1

212 aining on cognitive performance and incident dementia outcomes for adults with normal cognition or mi

213 Estimates of the absolute risk of MCI or dementia, particularly over short time intervals, are se

214 25/Cdk5 in tauopathy, we used frontotemporal dementia patient-derived induced pluripotent stem cells

215 y impairment is an early clinical feature of dementia patients, but the molecular and cellular mechan

216 Considering their modest effectiveness in dementia patients, the increased risk of adverse events

217 en, behavioral and psychological symptoms of dementia, pharmacotherapy with antidementia drugs, and u

218 ve impairment, and 180 patients with AD with dementia, plasma NFL correlated with CSF NFL (Spearman r

219 primary endpoint more sensitive in this pre-dementia population, is needed.

220 gnificantly more cases categorised as non-AD dementia post-API (from 11 to 23).

221 First, Kraepelin's new categories of dementia praecox and manic-depressive insanity were too

222 Dementia prevention in unmarried people should focus on

223 ncidence rates since the start of a national dementia program in 2003 (-0.025; 95% CI -0.062 to 0.011

224 ural and language variants of frontotemporal dementia, progressive supranuclear palsy and corticobasa

225 spectrum of clinical phenotypes dominated by dementia, psychiatric changes, movement disorders and up

226 core only, the 3-year progression risk to AD dementia ranged from 26% (95% CI, 19%-34%) in younger me

227 standard clinical instruments: the Clinical Dementia Rating Scale sum of boxes, a verbal memory test

228 SE; 0 [worst] to 30 [best] points), Clinical Dementia Rating Sum of Boxes (CDR-Sum of Boxes; 0 [best]

229 Patients with dementia receiving DCM had an increased chance of receiv

230 ranulin in the development of frontotemporal dementia-related deficits, we generated two neuronal pro

231 esymptomatic subjects bearing frontotemporal dementia-related pathogenic mutations.

232 metastatic cancer (requiring ICU), end-stage dementia (requiring ICU and transitioned to comfort-care

233 (8.9%) and 223,765 (18.8%) developed AD and dementia, respectively, and 26% to 33% died without eith

234 ents with behavioural variant frontotemporal dementia revealed that the inability to subjectively dif

235 CI, cholinesterase inhibitors did not reduce dementia risk (1 trial, low strength of evidence).

236 A), and cardiovascular risk factors increase dementia risk.

237 ter developing dementia or the AD subtype of dementia, separately, using adjusted Cox proportional ha

238 tors in patients (i.e., diagnosis, age, sex, dementia severity, and patient mental health).

239 e-wide association studies in frontotemporal dementia showed limited success in identifying associate

240 reported as a risk factor for frontotemporal dementia spectrum and Alzheimer's disease in an initial

241 ene encoding tau (MAPT) cause frontotemporal dementia spectrum disorders.

242 resident characteristics (i.e., age, gender, dementia stage, function, comorbidity, psychoactive medi

243 202 respondents aged 65 years and older with dementia status assessment.

244 cs halved after the introduction of national dementia strategies.

245 ia after the introduction of the UK National Dementia Strategy (p<0.0001).

246 uropsychiatric symptoms, and the accuracy of dementia subtype diagnosis.

247 hological diagnosis to clinical diagnosis of dementia subtype.

248 FUS) are hallmarks of ALS and frontotemporal dementia subtypes.

249 HA supplementation in predementia but not AD dementia suggests that early omega-3 supplementation may

250 analysis, especially in subcortical vascular dementia (SVaD) patients.

251 with the interval between onset of motor and dementia symptoms (beta -4.0, 95% CI -5.5 to -2.6; p<0.0

252 g married is associated with reduced risk of dementia than widowed and lifelong single people, who ar

253 Alzheimer's disease (AD) is a type of dementia that causes major issues for patients' memory,

254 l brain connections, and are associated with dementia that is independent of Alzheimer's disease path

255 r protective mechanisms in people at risk of dementia that might facilitate new therapeutic strategie

256 he relationship between frailty and incident dementia, the analyses were repeated according to lower

257 y of community-dwelling older adults without dementia, those with prior TBI with LOC were more likely

258 c lateral sclerosis (ALS) and frontotemporal dementia, though the mechanisms by which such expansions

259 ight be useful for differential diagnosis in dementia to determine the vascular component.

260 o to discriminate between different types of dementia to provide the appropriate management and treat

261 formance, cognitive decline, and dementia (N dementia/total = 195/7,499).

262 evidence on the most effective approaches to dementia training and education for hospital staff.

263 separately for mild cognitive impairment and dementia trials.

264 rebral perfusion (mL/100mL/min) with risk of dementia (until 2015) using a Cox model, adjusting for a

265 Alzheimer disease (AD), and 35% of vascular dementia (VaD).

266 The prevalence of dementia varies around the world, potentially contribute

267 bsequent development of dementia (eg, senile dementia, vascular dementia, frontotemporal dementia, an

268 iagnostic accuracy for patients with AD with dementia vs controls (area under the receiver operating

269 sed in 104 (5.1%) individuals, and all-cause dementia was diagnosed in 255 (12.5%) participants, incl

270 The association between frailty and incident dementia was significant for adults in the upper three q

271 Incident all-cause dementia was the main outcome measure, and single- and d

272 ssessed in 3 different ways, and the risk of dementia.We measured plasma 25-hydroxyvitamin D [25(OH)D

273 th cardiopulmonary bypass without documented dementia were enrolled in 2009.

274 ents with behavioural variant frontotemporal dementia were less motivated, and therefore less success

275 Diagnoses of Alzheimer disease and vascular dementia were secondary outcome measures.

276 arly stages of Alzheimer's disease (AD) from Dementia with Lewy Bodies (DLB), on peptide level the hi

277 c inclusions in Parkinson's disease (PD) and dementia with Lewy bodies (DLB).

278 Segregation of AD from dementia with Lewy bodies (DLB; n = 34) was achieved wit

279 follow-up, 25 of 74 subjects (34%) developed dementia with Lewy bodies (n = 13), Parkinson disease (n

280 Alzheimer's disease, dementia with Lewy bodies and genetic neurodegenerative

281 ved to exert toxic effects at the synapse in dementia with Lewy bodies and other alpha-synucleinopath

282 ein is found at the presynaptic terminals of dementia with Lewy bodies cases mainly in the form of sm

283 r knowledge, no large-scale genetic study of dementia with Lewy bodies has been done.

284 Dementia with Lewy bodies is the second most common form

285 Dementia with Lewy bodies is the second most common form

286 er burden, are also reported to be higher in dementia with Lewy bodies than in Alzheimer's disease.

287 ally, we estimate the heritable component of dementia with Lewy bodies to be about 36%.

288 ucleinopathies, such as Parkinson's disease, dementia with Lewy bodies, and multiple systems atrophy.

289 diagnosis in over 25% (Alzheimer's disease, dementia with Lewy bodies, and progressive supranuclear

290 human brain samples from five patients with dementia with Lewy bodies, five patients with Alzheimer'

291 ield, partly because of similarities between dementia with Lewy bodies, Parkinson's disease, and Alzh

292 Dementia with Lewy bodies, Parkinson's disease, and Mult

293 ed in blocks from the striatum of cases with dementia with Lewy bodies.

294 the structure and function of the synapse in dementia with Lewy bodies.

295 phosphorylated alpha-synuclein pathology in dementia with Lewy bodies.

296 long latency and incomplete penetrance of AD dementia with respect to Abeta pathology, we hypothesize

297 operative delirium are at risk of developing dementia within 5 years after cardiac surgery.

298 g general-practitioner-recorded diagnosis of dementia within the electronic health records.

299 studies suggest that other neurodegenerative dementias would also benefit from imaging at ultrahigh r

300 second most common form of neurodegenerative dementia, yet scarce evidence is available about its pro